Disclosure of shareholdings - FMR LLC

8 March 2010, 07:15 CET

Nobel Biocare received notification that FMR LLC reduced its holding in Nobel Biocare per 2 March 2010 to 5,998,817 registered shares which represented 4.85% of the registered share capital at that time.

Media contact

Name: Nicolas Weidmann (Senior Vice President Communications)
Tel: +41 43 211 42 80; +41 79 372 29 81
E-mail: nicolas.weidmann@nobelbiocare.com

Investor contact

Name: Süha Demokan (Head of Investor Relations)
Tel: +41 43 211 42 30; +41 79 430 81 46
E-mail: suha.demokan@nobelbiocare.com

Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutions from tooth to root, for single tooth to completely edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActive™, Brånemark System® and NobelReplace®), individualized prosthetics and equipment (NobelProcera™), guided surgery solutions and biomaterials. Nobel Biocare has over 2,400 employees and recorded revenue of EUR 569.2 million in 2011. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 34 direct sales organizations.

Disclaimer
This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

Investor contacts

Süha Demokan

Süha Demokan

Head of Investor Relations

Nobel Biocare Management AG  
P.O. Box
CH - 8058 Zurich-Airport
Switzerland

+41 43 211 42 30

+41 79 430 81 46

+41 43 211 42 42

Give us your feedback!

Summarize your comments
Email